| Market Cap | 30.91M | P/E | - | EPS this Y | 69.30% | Ern Qtrly Grth | - |
| Income | -86.65M | Forward P/E | -0.56 | EPS next Y | 76.90% | 50D Avg Chg | -20.00% |
| Sales | 14.67M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -62.00% |
| Dividend | N/A | Price/Book | 0.88 | EPS next 5Y | - | 52W High Chg | -93.00% |
| Recommedations | 1.00 | Quick Ratio | 2.77 | Shares Outstanding | 1.48M | 52W Low Chg | 32.00% |
| Insider Own | 11.80% | ROA | -52.44% | Shares Float | 1.27M | Beta | 1.85 |
| Inst Own | 43.86% | ROE | -225.93% | Shares Shorted/Prior | 33.59K/42.34K | Price | 0.70 |
| Gross Margin | 98.17% | Profit Margin | - | Avg. Volume | 470,982 | Target Price | 30.00 |
| Oper. Margin | -527.52% | Earnings Date | May 9 | Volume | 455,940 | Change | 3.89% |
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| KAYNE RICHARD A | 10% Owner 10% Owner | Oct 31 | Buy | 0.27 | 278,239 | 75,125 | 5,375,225 | 11/02/23 |
| KAWAS LEEN | 10% Owner 10% Owner | Oct 31 | Buy | 0.26 | 24,332 | 6,326 | 4,391,432 | 11/02/23 |
| Mayer Eldon C. III | Ex VP & Chief Commer.. Ex VP & Chief Commerc. Officer | Mar 17 | Sell | 1.07 | 4,395 | 4,703 | 56,073 | 03/21/23 |
| Dietz Thomas John | Director Director | Jan 23 | Buy | 1.4316 | 50,000 | 71,580 | 50,000 | 01/25/23 |
| Murray Christine | Director Director | Dec 29 | Sell | 1.2208 | 5,000 | 6,104 | 11,000 | 01/03/23 |
| Dietz Thomas John | Director Director | Dec 22 | Sell | 1.169 | 22,500 | 26,302 | 21,000 | 12/27/22 |
| Glenn Jeffrey S | Director Director | Dec 22 | Buy | 1.2795 | 100,000 | 127,950 | 182,355 | 12/27/22 |
| Apelian David | Director Director | Aug 16 | Sell | 9.8061 | 5,000 | 49,030 | 11,000 | 08/18/22 |
| Ryali Sriram | Chief Financial Offi.. Chief Financial Officer | Mar 14 | Sell | 5.5973 | 2,266 | 12,683 | 41,566 | 03/14/22 |
| Mayer Eldon C. III | Ex VP & Chief Commer.. Ex VP & Chief Commerc. Officer | Mar 14 | Sell | 5.5973 | 1,657 | 9,275 | 60,468 | 03/14/22 |
| Mayer Eldon C. III | Ex VP & Chief Commer.. Ex VP & Chief Commerc. Officer | Jan 07 | Sell | 4.9501 | 1,560 | 7,722 | 46,125 | 01/11/22 |
| Dietz Thomas John | Director Director | Apr 12 | Buy | 8.49 | 2,500 | 21,225 | 37,500 | 04/12/21 |